Akeso Biopharma has reached a significant milestone in cancer treatment by enrolling the first patient in its Phase 3 clinical trial for head and neck squamous cell carcinoma (HNSCC). This trial, identified as AK117-302, investigates the efficacy of Ivonescimab, a PD-1/VEGF bispecific antibody, in combination with Ligufalimab, a next-generation CD47 monoclonal antibody. Both therapies will be compared against Pembrolizumab, the current first-line treatment for patients with recurrent or metastatic HNSCC who express PD-L1 at a score of 1 or higher.
A Groundbreaking Trial
The AK117-302 trial marks the first Phase 3 study globally to explore a CD47 monoclonal antibody in the context of solid tumors. This trial is not only the fifth Phase 3 study for Ivonescimab but also the third to compare it with Pembrolizumab, reinforcing Akeso’s initiative to lead in cancer immunotherapy. The results aim to establish a new standard of care, potentially benefiting a larger population of HNSCC patients through a well-structured clinical development strategy.
The Urgent Need for Effective Treatments
Globally, head and neck cancer presented 770,000 new cases in 2022, with China accounting for 84,000 of those. HNSCC specifically comprises over 90% of these cases. Alarmingly, the five-year survival rate for recurrent or metastatic HNSCC is only 3.6%. Despite advancements in targeted therapies and immunotherapies, the median overall survival remains below one year. Pembrolizumab has been recognized as the standard first-line treatment, yet there is a pressing requirement for more effective therapies to improve long-term survival outcomes for these patients.
Promising Early Data
During the 2024 European Society for Medical Oncology (ESMO) Congress, Akeso presented preliminary data indicating that the combination of Ivonescimab and Ligufalimab exhibits significant tumor reduction and survival benefits for patients with HNSCC. This combination appears to offer rapid tumor shrinkage, positioning it as a potentially transformative immunotherapy option that may outperform existing PD-1 therapies.
The Mechanism of Action
Ligufalimab, an innovative humanized IgG4 anti-CD47 antibody developed by Akeso, operates by binding to CD47 on tumor cells. This action interrupts the interaction between CD47 and SIRPα, enhancing the phagocytic activity of immune cells against tumor cells and thereby inhibiting tumor growth. This mechanism represents a promising avenue for improving outcomes in cancer treatment.
Ongoing Clinical Investigations
In addition to the AK117-302 trial, several Phase 2 studies are underway to assess Ligufalimab’s effectiveness in various combinations, including treatments for hematological and solid tumors. These trials focus on its use in conjunction with azacitidine and other therapies, showing encouraging efficacy and safety profiles without significant dose-limiting toxicity.
Ivonescimab’s Unique Position
Ivonescimab stands out as a novel first-in-class PD-1/VEGF bispecific immunotherapy, developed independently by Akeso. It is marketed as SMT112 in regions such as the United States and Europe. Recently, it received approval in China for treating locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in patients who have not responded to previous EGFR TKI treatments. Akeso is actively pursuing six registrational trials for Ivonescimab against anti-PD-1/L1 therapeutics across various indications.
Akeso’s Commitment to Innovation
Founded in 2012, Akeso Biopharma has established itself as a leader in the biopharmaceutical industry, focusing on innovative biological medicines. Equipped with a unique end-to-end drug development platform and advanced manufacturing capabilities, Akeso is advancing a robust pipeline of over 50 innovative assets targeting cancer, autoimmune diseases, and other major health challenges. Among these, 22 candidates are in clinical trials, including 11 bispecific antibodies and antibody-drug conjugates, which underscores the company’s commitment to research and development.
In summary, Akeso Biopharma’s initiation of the Phase 3 trial for Ivonescimab and Ligufalimab represents a significant advancement in the treatment landscape for head and neck cancer. As the trial progresses, it has the potential to redefine therapeutic options and improve survival rates for patients facing this challenging disease.
Key Takeaways
- Akeso has enrolled the first patient in a Phase 3 trial for HNSCC, comparing Ivonescimab with Pembrolizumab.
- The trial is the first of its kind globally to investigate CD47 monoclonal antibodies for solid tumors.
- Early data indicates promising tumor reduction and survival benefits with the combination therapy.
- Akeso is progressing with multiple clinical trials to expand the applications of its innovative therapies.
- The company is dedicated to developing first-in-class and best-in-class treatments for various diseases.
Read more → bandsnews.com